ReviewNeuromolecular medicine2026
Research Progress on Regulating Neuroinflammation After Spinal Cord Injury by Targeting the cGAS-STING Pathway.
Review in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neuroinflammation following secondary injury in spinal cord injury (SCI) constitutes a major obstacle to functional recovery. Endogenous danger signals, particularly mitochondrial DNA (mtDNA) released post-injury, can activate the cGAS-STING pathway, thereby modulating the activation state of microglia and macrophages toward a pro-inflammatory phenotype. This process unfolds within a highly interconnected network involving Toll-like receptor (TLR) signaling, reactive oxygen species (ROS), NLRP3 inflammasome assembly, and cytokine cascades. Through crosstalk with the NLRP3 inflammasome, the cGAS-STING pathway can enhance cellular susceptibility to pyroptosis. The ultimate execution of pyroptotic cell death remains contingent upon additional downstream events, including the activation of Caspase-1 and the cleavage of Gasdermin D. The state of microglia and macrophages is dynamically regulated by a convergence of multiple signaling pathways. Furthermore, the cGAS-STING pathway engages in complex bidirectional interactions with autophagy, underscoring its multifaceted regulatory functions. This review explores emerging intervention strategies targeting this pathway, including small-molecule inhibitors/agonists, genetic interventions, and smart nanomaterials, aimed at achieving precise immunomodulation within the neuroimmune microenvironment. However, the clinical translation of this field still faces significant challenges, primarily concerning issues of spatiotemporal-specific modulation, drug delivery efficiency, and interspecies differences. Future research should focus on elucidating these intricate mechanisms and developing advanced drug delivery systems to facilitate the translation of this therapeutic target from a conceptual framework into clinically effective treatment modalities.
Indexed as
Identifiers
42533158What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.